Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non‐small cell lung cancer

BACKGROUND: Recent studies have revealed a reduction in the skeletal muscle area in patients with advanced non‐small cell lung cancer (NSCLC) after chemotherapy. EGFR and ALK tyrosine kinase inhibitor (TKI)‐based therapies are less cytotoxic than chemotherapy, but differences in skeletal muscle mass...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Thorac Cancer
Autores principales: Kakinuma, Kazutaka, Tsuruoka, Hazime, Morikawa, Kei, Furuya, Naoki, Inoue, Takeo, Miyazawa, Teruomi, Mineshita, Masamichi
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons Australia, Ltd 2017
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754304/
https://ncbi.nlm.nih.gov/pubmed/29067769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12545
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares